Skip to main content

Table 3 miR-22 validated targets from TCGA data set anti-correlation analysis

From: Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study

MicroRNA

Gene

R-Spearman

p-value

PUBMED ID

hsa-miR-22-3p

CDK6

−0.351

0.016

20,371,350

hsa-miR-22-3p

CDKN1A

−0.433

0.003

23,582,783\21,572,407

hsa-miR-22-3p

LONP2

−0.312

0.033

23,824,327\27,418,678

hsa-miR-22-3p

TFRC

−0.303

0.039

19,135,902

hsa-miR-22-3p

ZNF460

−0.424

0.003

23,592,263